These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2051302)

  • 1. [Pharmaceutical research strategies in Alzheimer's disease].
    Wülfert E
    J Pharm Belg; 1991; 46(1):67-77. PubMed ID: 2051302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?
    Palmer AM; Gershon S
    FASEB J; 1990 Jul; 4(10):2745-52. PubMed ID: 2165009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI.
    Teipel SJ; Flatz WH; Heinsen H; Bokde AL; Schoenberg SO; Stöckel S; Dietrich O; Reiser MF; Möller HJ; Hampel H
    Brain; 2005 Nov; 128(Pt 11):2626-44. PubMed ID: 16014654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia.
    Chan-Palay V
    J Comp Neurol; 1988 Jul; 273(4):543-57. PubMed ID: 2463283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease.
    Boissiere F; Faucheux B; Ruberg M; Agid Y; Hirsch EC
    Exp Neurol; 1997 May; 145(1):245-52. PubMed ID: 9184126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
    Terry AV; Buccafusco JJ
    J Pharmacol Exp Ther; 2003 Sep; 306(3):821-7. PubMed ID: 12805474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease.
    Gilmor ML; Erickson JD; Varoqui H; Hersh LB; Bennett DA; Cochran EJ; Mufson EJ; Levey AI
    J Comp Neurol; 1999 Sep; 411(4):693-704. PubMed ID: 10421878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function.
    Gibbs RB
    Exp Neurol; 1998 Jun; 151(2):289-302. PubMed ID: 9628764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic systems in Alzheimer's disease.
    Francis PT
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S15-21. PubMed ID: 12973746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. m2 muscarinic acetylcholine receptor-immunoreactive neurons are not reduced within the nucleus basalis in Alzheimer's disease: relationship with cholinergic and galaninergic perikarya.
    Mufson EJ; Jaffar S; Levey AI
    J Comp Neurol; 1998 Mar; 392(3):313-29. PubMed ID: 9511920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative therapy of Alzheimer's disease via supplementation with choline acetyltransferase.
    Fu AL; Li Q; Dong ZH; Huang SJ; Wang YX; Sun MJ
    Neurosci Lett; 2004 Sep; 368(3):258-62. PubMed ID: 15364407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neurotransmitters in Alzheimer's disease].
    Kristensen MO
    Ugeskr Laeger; 1990 Jul; 152(30):2165-8. PubMed ID: 1975961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups.
    Bird TD; Stranahan S; Sumi SM; Raskind M
    Ann Neurol; 1983 Sep; 14(3):284-93. PubMed ID: 6227276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer's disease.
    Wu CK; Thal L; Pizzo D; Hansen L; Masliah E; Geula C
    Exp Neurol; 2005 Oct; 195(2):484-96. PubMed ID: 16085017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease.
    Lehéricy S; Hirsch EC; Cervera-Piérot P; Hersh LB; Bakchine S; Piette F; Duyckaerts C; Hauw JJ; Javoy-Agid F; Agid Y
    J Comp Neurol; 1993 Apr; 330(1):15-31. PubMed ID: 8468401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation].
    Dubois B; Hauw JJ; Ruberg M; Serdaru M; Javoy-Agid F; Agid Y
    Rev Neurol (Paris); 1985; 141(3):184-93. PubMed ID: 4001706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinergic modulation, visual function and Alzheimer's dementia.
    Nobili L; Sannita WG
    Vision Res; 1997 Dec; 37(24):3559-71. PubMed ID: 9425531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NGF and the treatment of Alzheimer's disease.
    Olson L
    Exp Neurol; 1993 Nov; 124(1):5-15. PubMed ID: 8282080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex.
    Hof PR; Cox K; Morrison JH
    J Comp Neurol; 1990 Nov; 301(1):44-54. PubMed ID: 2127598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternatives in the treatment of memory loss in patients with Alzheimer's disease.
    Volger BW
    Clin Pharm; 1991 Jun; 10(6):447-56. PubMed ID: 2065522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.